NEW YORK (GenomeWeb) – Meridian Bioscience said after the close of the market on Monday that its preliminary fiscal first quarter revenues are expected to be down about 2 percent year over year.

For fiscal Q1 2019, the company said that revenues are anticipated to be in the range of $51 million to $51.5 million compared to $52.3 million a year ago. The analysts' average estimate is $53.5 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.